OBJECTIVE To evaluate the role of cancer antigen CA15-3 in the diagnosis, prognosis, followup and treatment of breast cancer. METHODS The case-control study was done from October 2009 to February 2011 at the Al-Basrah Hospital in Basrah, Iraq. Blood samples were collected from 30 women with primary breast cancer before the invasive procedure. Another set of blood samples were collected from 2...

BACKGROUND Serum HER2 testing allows the determination of real-time HER2 status during clinical course. The aim of this investigation was: (1) to study the prognostic significance of serum HER2 at the time of first diagnosis of metastatic breast cancer and (2) to evaluate its relationship to CA15-3 which is a surrogate marker for tumor load. MATERIALS AND METHODS Serum samples of 120 breast c...

Breast cancer (BC) is a genetic disease in the mammary glands' ducts and lobules, with ductal cancers comprising most of malignancies. Biomarkers can provide an assessment diagnosis prediction. The study aims to compare expression serum (miR-21-5p) CA 15-3 Iraqi population as more efficient biomarkers, then checked MiRNA-21 main characters biomarker comparison (CA15-3) levels. Circulating miRNA...

Objective: To evaluate the role of cancer antigen CA15-3 as prognostic marker in breast cancer patient. Methods: The prospective study was done from November 2013 to October 2014 at Deparment of surgery, MGM Medical college and M.Y. Hospital group, Indore.This was a prospective study done on 31 patients with breast cancer. Blood samples were collected from all the patients and from the other pa...

Twist1 overexpression is involved in epithelial‑mesenchymal transition resulting in migration and metastasis of breast cancer. Carcinoma antigen 15‑3 (CA15‑3) is widely used to monitor the prognosis for patients after treatment. However, the significance of Twist1 in axillary lymph nodes (ALN) and CA15‑3 for co‑examination for survival rates remains to be elucidated. The present study aimed to ...

Previous studies have indicated that carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) levels are both independent prognostic factors in breast cancer. However, the utility of CEA and CA15-3 levels as conventional cancer biomarkers in patients with triple-negative breast cancer (TNBC) remains controversial. The current study was performed to explore the predictive value of pre-the...

Cancer antigen 15-3 (CA15-3) is considered as a marker for breast cancer recurrence. However, we encountered a case where the patient showed postoperative elevation of the CA15-3 level due to pernicious anemia without evidence of breast cancer recurrence. The patient was a 60-year-old postmenopausal woman. She had undergone partial mastectomy and sentinel lymph node biopsy (SLNB) for her T1 lef...

PURPOSE To assess the relationship between the kinetics of the serum CA15-3 level and the five-year disease-free survival rate of breast cancer patients. METHODS The subjects of this study, 297 women who were diagnosed with breast cancer, were the subset of patients operated on at Kosin University Gospel Hospital from January 2008 to December 2010. We evaluated the change of serum CA15-3 leve...

The value of serum tumour markers in the prognosis of patients with breast cancer is controversial. This prospective study in Yazd, Islamic Republic of Iran, assessed the value of the tumour markers carcinoembryonic antigen (CEA) and cancer antigen (CA) 15-3 in 159 patients with primary breast cancer. CEA and CA15-3 assays (mean 14 per patient) were performed at diagnosis, end of surgery and ch...

The main goals of the clinical use of tumor markers are to evaluate the adequacy of the treatment, monitor recurrence and follow up response to the treatment applied. For this purpose a baseline level for the commonly used tumor marker must be known at the time of initial diagnosis, before any therapy, in order to compare with the tumor marker levels which will be obtained after the treatment a...